Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Summary
SB4472, the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, would extend the existing federal ALS research and therapy-access program through fiscal year 2031. The bill reauthorizes grant authority under the Accelerating Access to Critical Therapies for ALS Act and makes several program changes intended to improve oversight and planning for ALS and related rare neurodegenerative disease initiatives.
In addition to extending the program, the bill requires the Secretary of Health and Human Services to review clinical trial status when considering grant renewals for investigational drugs, including by requesting interim clinical trial data from manufacturers. It also clarifies that a qualifying phase 3 clinical trial includes combined phase 2/3 trials and planned phase 3 trials that have not yet begun enrolling participants. The bill further directs FDA to publish an updated action plan on ALS and other rare neurodegenerative diseases within one year, including implementation steps, resource needs, and coordination with non-ALS rare disease communities, and it delays the GAO reporting deadline while extending the report’s lookback period.
Impact
The bill would amend the Accelerating Access to Critical Therapies for ALS Act, a federal law codified in part at 21 U.S.C. 360ee note and related provisions, by extending its sunset date from 2026 to 2031 and revising reporting and grant-review requirements. It would affect FDA and HHS administration of ALS research grants, clinical-trial-related grant renewals, and federal planning for rare neurodegenerative disease policy. The bill also expands the scope of federal oversight and transparency by requiring updated FDA action planning and a later GAO review of the program’s effects.
Sentiment
The available legislative history suggests generally favorable sentiment. The bill was ordered to be reported by the Senate Committee on Health, Education, Labor, and Pensions with an amendment in the nature of a substitute and without any recorded votes or transcripted opposition in the provided materials. That procedural outcome indicates committee support for continuing the program and refining its implementation rather than major controversy.
Contention
The main points of potential contention are administrative and policy-oriented rather than ideological. The bill increases federal oversight of grant renewals by requiring review of interim clinical trial data, which could raise concerns from drug manufacturers or researchers about reporting burdens and confidentiality. Another possible issue is the bill’s broader framing of ALS policy to include other rare neurodegenerative diseases, which may prompt questions about program scope, resource allocation, and whether FDA and HHS have sufficient capacity to meet the added planning and reporting requirements. No specific opposition is documented in the provided record.